Search This Site:
Beds-Luton-MK-CCG-Logo-2021

Joint Formulary Newsletter

Bedfordshire and Luton Joint Formulary Newsletter

March 2021, Number 6

FORMULARY UPDATE

The Bedfordshire and Luton Joint Formulary (a combined medicines formulary for use by BCCG, LCCG, Bedford Hospital and the Luton and Dunstable University Hospital) is now ‘live’. It can be accessed here

Unless otherwise stated decisions made apply to all organisations in the Joint Formulary Group.

FORMULARY TRAFFIC LIGHT STATUS INFORMATION
RED RED - Hospital Only - to be prescribed by a specialist and supplied from secondary care ONLY throughout treatment
AMBER Amber medicines are considered suitable for GP prescribing following specialist initiation
GREEN These medicines are appropriate for initiation in both primary and secondary care. Prescribing is appropriate within licensed or local recommendations
SCG Shared Care - These medicines require specialist initiation and stabilisation. Ongoing division of responsibility for drug and disease monitoring between specialist and GP by a Shared Care Guideline (SCG). If no SCG in place, status reverts to RED.
BLACK A decision has been made by either or both the local or national NHS not to routinely commission this preparation for its licensed indications. DO NOT PRESCRIBE
The following ADDITIONS to the Joint Formulary were agreed at the JPC Committee Meeting
  • DEKAs® Plus Vitamins :- Amber formulary status – Specialist initiations with GP to continue prescribing for patients with Cystic Fibrosis.
    • Specialist centres have been requesting GPs to prescribe DEKAs® Plus but have encountered resistance as it is currently ‘non-formulary’ in primary care.
    • The committee agreed to the addition of DEKA vitamins to the Joint Formulary to allow GP prescribing after specialist initiation.

 

Hospital Drug and Therapeutic Committee Updates

Drugs and Therapeutics and Prescribing Committees’ decisions are noted for information:

Catephen (camellia sinensis) 10% ointment – Added to the Joint formulary  – Red formulary status

CCG Prescribing Committees

BLMK Prescribing Committee

Addition of preferred brands

  • Eyzeetan (Bimatoprost / Timolol 0.3mg/5mg/ml) preservative free eye drops Eythalm (dexamethasone 0.1%) preservative free eye drops
  • Zacco 10mg/5ml Oral Suspension (clobazam)
Wound Care Formulary Group (Ratified by the JPC)
  • No update from the Wound Care Group
Decisions Made By Joint Formulary Group (Ratified by the JPC)
  1. Propaderm 1 in 10 ointment added in line with BAD specials list
  2. Selegiline lyophilisate 1.25mg – discontinued, moved to non-formulary
  3. Nuelin – discontinued, moved to non-formulary
  4. Dorzolamide – to reflect generic prescribing
  5. Dapoxetine ‘black’ status added to reflect that it has been reviewed by JPC as not suitable for prescribing.
NICE Updates

Joint Formulary updates following publication of NICE Technology Appraisal Guidance

 CCG Commissioned

The following CCG commissioned items have received positive NICE TA’s and have been added to the Joint formulary as a result:-

  • Liraglutide (Saxenda®) for managing overweight and obesity (NICE TA 664)

NB: This is a different preparation to Liraglutide (Victoza®) which is licensed to treat type 2 diabetes.

RED formulary status : To be prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service only ; No GP Prescribing

 

  • Upadacitinib for treating severe rheumatoid arthritis, (NICE TA 665).

The RA treatment pathway has been updated accordingly.

RED formulary status : To be prescribed in secondary care by a specialist; No GP Prescribing.

 

  • Brolucizumab for treating wet age-related macular degeneration (NICE TA 672).

An updated Ophthalmology Intravitreal Treatment pathway will be available shortly.

RED formulary status : To be prescribed in secondary care by a specialist; No GP Prescribing.

 

RED formulary status : To be prescribed in secondary care by a specialist; No GP Prescribing.

 

  • Filgotinib for treating moderate to severe rheumatoid arthritis (NICE TA 676)This is the first NICE TA providing a treatment option for moderate disease as the other NICE TAs for biologics and JAK inhibitors all relate to the use for treating severe disease only. The RA treatment pathway has been updated in include this treatment option.

RED formulary status : To be prescribed in secondary care by a specialist; No GP Prescribing.

 

  • Dapagliflozin for treating chronic heart failure with reduced ejection fraction (NICE TA 679)

Amber formulary status – Specialist initiations with GP to continue prescribing.

 

  • Baricitinib for treating moderate to severe atopic dermatitis (NICE TA 681)

RED formulary status : To be prescribed in secondary care by a specialist; No GP Prescribing.

 

RED formulary status : To be prescribed in secondary care by a specialist; No GP Prescribing.

 

NHSE Commissioned

The following NHSE commissioned items have received positive NICE TA’s and have been added to the Joint formulary as a result:- All of these drugs below have a RED formulary status : To be prescribed in secondary care by a specialist; No GP Prescribing.

 

  • Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (NICE TA 660)
  • Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura (NICE TA 667)
  • Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy, (NICE TA 673)(Funding via Cancer Drugs Fund)
Scroll to Top